Comparative transcriptomics of salivary basal cell adenoma and adenocarcinoma sustain linear neoplastic evolution and intertumor heterogeneity: classification and biological implications
It remains uncertain whether basal cell adenoma (BCA) and basal cell adenocarcinoma (BCAC) of the salivary gland represent two distinct neoplasms or temporal stages of a single entity. The issue is central to reconciling their shared phenotypic resemblance and protracted behavior with current pathologic classification. We conducted a transcriptomic analysis on a cohort of both pathologic forms and correlated the findings with the clinicopathologic features using RNA extracted from fresh frozen samples of 25 salivary basal tumors (five BCAs and 20 BCACs) and eight instances of metastatic basal cell carcinomas (BCCs) to parotid glands. Unsupervised analysis revealed shared and intertumoral transcriptome differences within and between BCA and BCAC and distinct segregation from metastatic dermal BCC. Transcriptomic profiling delineated two intermixed subgroups of salivary basal cell neoplasms (SBNs); SBN-I group enriched with adverse pathologic features and SBN-II that lacked any of these features except for a single case. The category with the most instances of adverse pathologic features (SBN-I) manifested upregulations of transcriptional factors linked to cell proliferation pathways (HOXB13, SOX21, MYB, and EN1 genes), while those lacking adverse pathologic features (SBN-II) demonstrated a high expression of the TFAP2B transcription- and differentiation-related pathways. Our transcriptomic findings support common neoplastic evolution and intertumoral heterogeneity of both pathologic forms of basal cell neoplasms and identify molecular pathways of potential biological and clinical significance. We therefore propose a nondeterministic designation of 'basal cell salivary neoplasms, noninvasive (adenoma)/invasive (adenocarcinoma)' as a platform that integrates conventional phenotypic classification and transcriptomic characteristics pending a classification consensus. © 2025 The Pathological Society of Great Britain and Ireland.
Authors
- Yoshitsugu Mitani (ORCID: https://orcid.org/0000-0002-8661-4702)
- Haneen Al‐Maghrabi (ORCID: https://orcid.org/0000-0003-3088-7717)
- Renata Ferrarotto (ORCID: https://orcid.org/0000-0002-3561-215X)
- Diana Bell
- Raissa Relator (ORCID: https://orcid.org/0000-0002-8153-2222)
- Ryan P. Goepfert (ORCID: https://orcid.org/0000-0002-3291-841X)
- Adel K. El‐Naggar (ORCID: https://orcid.org/0000-0002-7175-9466)
- Irene Y. Chen (ORCID: https://orcid.org/0000-0001-5202-2111)
- Tatiana V. Karpinets (ORCID: https://orcid.org/0000-0002-3668-8148)
- Jianhua Zhang (ORCID: https://orcid.org/0000-0001-5412-9860)
- Lauren Hilder
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- University of Pittsburgh (US)
- King Faisal Specialist Hospital & Research Centre (SA)
Publication Details
- Journal
- The Journal of Pathology
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1002/path.6424
- Primary Topic
- Salivary Gland Tumors Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Institute of Dental and Craniofacial Research